0001395064-22-000069.txt : 20220509
0001395064-22-000069.hdr.sgml : 20220509
20220509061039
ACCESSION NUMBER: 0001395064-22-000069
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220503
FILED AS OF DATE: 20220509
DATE AS OF CHANGE: 20220509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD
CENTRAL INDEX KEY: 0001395064
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41365
FILM NUMBER: 22903128
BUSINESS ADDRESS:
STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-8668
BUSINESS PHONE: 81332782111
MAIL ADDRESS:
STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-8668
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Takeda Vaccines, Inc.
CENTRAL INDEX KEY: 0001905616
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41365
FILM NUMBER: 22903127
BUSINESS ADDRESS:
STREET 1: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 781.266.5387
MAIL ADDRESS:
STREET 1: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HilleVax, Inc.
CENTRAL INDEX KEY: 0001888012
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 STATE ST.
STREET 2: SUITE 100
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: (617) 213-5054
MAIL ADDRESS:
STREET 1: 75 STATE ST.
STREET 2: SUITE 100
CITY: BOSTON
STATE: MA
ZIP: 02109
3/A
1
wf-form3a_165209102472594.xml
FORM 3/A
X0206
3/A
2022-05-03
2022-04-29
0
0001888012
HilleVax, Inc.
HLVX
0001395064
TAKEDA PHARMACEUTICAL CO LTD
1-1, NIHONBASHI-HONCHO 2-CHOME
CHUO-KU, TOKYO
M0
103-8668
JAPAN
0
0
1
0
0001905616
Takeda Vaccines, Inc.
75 SIDNEY STREET
CAMBRIDGE
MA
02139
0
0
1
0
Common Stock
840500
I
See Explanation of Responses
Warrant (Right to Buy)
0.0001
2022-05-03
2031-07-02
Common Stock
5883500.0
I
See Explanation of Responses
Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of 840,500 shares of Common Stock and a Warrant to purchase 5,883,500 shares of Common Stock; each held by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
Exercise price is $0.0000595 following April 22, 2022 1.681-for-1 forward stock split of the Issuer's common stock.
This amendment is being filed to correct the reporting person's initial Form 3 filed on April 29, 2022 to reflect (a) a 1.681-for-1 forward stock split of the Issuer's common stock effected on April 22, 2022 which resulted in (i) an increase in the reporting persons ownership of (x) common stock from 500,000 to 840,500 and (y) warrants from 3,500,000 to 5,883,500 and (ii) the exercise price of the warrants changing from $0.0001 to $0.0000595 and (b) a correction to the date on which the Warrant is exercisable, from April 28, 2022 to May 3, 2022, the latter reflecting the date on which the Issuer's initial public offering was consummated and the date on which the Warrant to purchase 5,883,500 shares of Common Stock became exercisable.
/s/ Yoshihiro Nakagawa, Global General Counsel of Takeda Pharmaceutical Company Limited
2022-05-09
/s/ Michael Martin, Authorized Signatory, Takeda Vaccines, Inc.
2022-05-09